Investors sentiment decreased to 1.56 in Q2 2019. Its down 3.17, from 4.73 in 2019Q1. It worsened, as 13 investors sold Revance Therapeutics, Inc. shares while 23 reduced holdings. 18 funds opened positions while 38 raised stakes. 41.43 million shares or 48.01% less from 79.68 million shares in 2019Q1 were reported.
Us Fincl Bank De holds 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC) or 545 shares. Wellington Group Llp accumulated 5.70 million shares or 0.02% of the stock. Glenmede Trust Na holds 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 3,450 shares. Principal Fincl invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). California State Teachers Retirement Systems reported 0% stake. Manufacturers Life Insur The holds 28,268 shares. Swiss Natl Bank reported 73,350 shares stake. Proshare Advsrs Limited Liability has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Nuveen Asset Management Ltd Liability Corporation, Illinois-based fund reported 203,337 shares. Franklin Inc owns 0.02% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 3.51M shares. United Automobile Association owns 82,862 shares. Citadel Advsrs Llc invested in 143,323 shares or 0% of the stock. Signaturefd Ltd Liability holds 0% or 66 shares. Voya Management Ltd Llc has 15,775 shares for 0% of their portfolio. Geode Mngmt Limited Com reported 561,114 shares.
The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) is a huge mover today! The stock decreased 17.57% or $3.54 during the last trading session, reaching $16.61. About 5.58 million shares traded or 1238.41% up from the average. Revance Therapeutics, Inc. (NASDAQ:RVNC) has declined 55.47% since December 4, 2018 and is downtrending. It has underperformed by 55.47% the S&P500.
The move comes after 7 months negative chart setup for the $749.25 million company. It was reported on Dec, 4 by Barchart.com. We have $15.61 PT which if reached, will make NASDAQ:RVNC worth $44.96 million less.
Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on February, 25. They expect $-1.01 earnings per share, up 9.82 % or $0.11 from last year’s $-1.12 per share. After $-0.96 actual earnings per share reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.21 % negative EPS growth.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage
Among 5 analysts covering Revance Therapeutics (NASDAQ:RVNC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Revance Therapeutics has $50 highest and $2000 lowest target. $30.40’s average target is 83.02% above currents $16.61 stock price. Revance Therapeutics had 8 analyst reports since June 11, 2019 according to SRatingsIntel. The company was maintained on Monday, October 14 by Mizuho. The company was upgraded on Wednesday, October 30 by Wells Fargo. H.C. Wainwright maintained the shares of RVNC in report on Tuesday, October 15 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, October 14.
More notable recent Revance Therapeutics, Inc. (NASDAQ:RVNC) news were published by: Benzinga.com which released: “75 Biggest Movers From Yesterday – Benzinga” on December 03, 2019, also Nasdaq.com with their article: “Asian Shares Slide As Trade Worries Deepen – Nasdaq” published on December 04, 2019, Finance.Yahoo.com published: “We’re Hopeful That Revance Therapeutics (NASDAQ:RVNC) Will Use Its Cash Wisely – Yahoo Finance” on October 08, 2019. More interesting news about Revance Therapeutics, Inc. (NASDAQ:RVNC) were released by: Finance.Yahoo.com and their article: “Did Changing Sentiment Drive Revance Therapeutics’s (NASDAQ:RVNC) Share Price Down A Worrying 59%? – Yahoo Finance” published on July 09, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? – Yahoo Finance” with publication date: October 30, 2019.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $749.25 million. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.